Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pulse Biosciences's Enterprise Value is $368.87 Mil.
Pulse Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-44.63 Mil. Therefore, Pulse Biosciences's EV-to-EBIT ratio for today is -8.27.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Pulse Biosciences's Enterprise Value is $368.87 Mil.
Pulse Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-43.42 Mil. Therefore, Pulse Biosciences's EV-to-EBITDA ratio for today is -8.49.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Pulse Biosciences's Enterprise Value is $368.87 Mil.
Pulse Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Pulse Biosciences's EV-to-Revenue ratio for today is .
Pulse Biosciences Enterprise Value Historical Data
The historical data trend for Pulse Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pulse Biosciences's Enterprise Value
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's Enterprise Value falls into.
Pulse Biosciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Pulse Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (NAS:PLSE) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Pulse Biosciences's current Enterprise Value is $368.87 Mil.
Pulse Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.63 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Pulse Biosciences's current Enterprise Value is $368.87 Mil.
Pulse Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.42 Mil.
Pulse Biosciences's current Enterprise Value is $368.87 Mil.
Pulse Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Pulse Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Pulse Biosciences (Pulse Biosciences) Business Description
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PLSE has been successfully added to your 